GILD · News · 20261030N

Medicare Drug Price Negotiation

GILEAD SCIENCES, INC. · 2026-10-30 · Importance 66 · Surprise 48

Gilead warned that Medicare pricing changes could reduce Biktarvy revenue by approximately $1.5 billion in 2028. The company expects Biktarvy sales to decline that year, while forecasting overall HIV revenue growth as newer treatments gain traction. CEO Daniel O’Day criticized the policy as a “pill penalty” that he said threatens drug innovation.